ProfileGDS5678 / 1440461_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 89% 89% 88% 90% 90% 88% 90% 90% 87% 88% 88% 90% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.602787
GSM967853U87-EV human glioblastoma xenograft - Control 27.0975289
GSM967854U87-EV human glioblastoma xenograft - Control 37.0415889
GSM967855U87-EV human glioblastoma xenograft - Control 47.1013888
GSM967856U87-EV human glioblastoma xenograft - Control 57.2656590
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.9985790
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.6480988
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.207890
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.1469190
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.6696387
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.8778288
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.8318588
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.1443790
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.7745588